English
Stock of the day
Telix Pharmaceuticals
Telix Pharmaceuticals sees substantial revenue growth despite a full-year net loss. The company's strategic investments and market trends suggest potential recovery and future profitability.
(AI video summary)
This video was created on 20 February 2026 for IG audiences by ausbiz.
ASX code: TLX
Telix records revenue growth amidst financial loss
Telix Pharmaceuticals, a notable name in biopharmaceuticals, reported a full-year net loss of US$5.3 million. However, revenue increased by 56% to nearly $804 million, exceeding expectations. The company is on track for nearly $1 billion in revenue next year, despite absorbing US$26.7 million in non-cash finance costs from acquiring LSE Radiopharmaceuticals. Chief Executive Officer (CEO) Dr Christian Brandenburg stressed the importance of vertical integration and regulatory milestones for global expansion.
Market analysis and technical insights
Telix's stock faced volatility, dropping to a key level around $8.50, with increased transaction volume indicating rising interest. The recent earnings brought surprises, suggesting a potential market trend shift. Analysts note that despite a decline from $28, the stock's behaviour shows potential for recovery if it breaks through $11.85
Investment outlook
Telix is investing heavily in research and development (R&D), with $200 to $240 million planned for the next year to strengthen its therapeutic pipeline. Management has projected revenue of US$950 million to US$970 million for the financial year (FY) 2026, with expected profitability by FY 2027.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Follow us online:
